Provided by Tiger Trade Technology Pte. Ltd.

Design Therapeutics, Inc.

14.99
-0.5700-3.66%
Post-market: 14.990.00000.00%19:31 EDT
Volume:552.12K
Turnover:8.46M
Market Cap:936.00M
PE:-12.69
High:15.83
Open:15.66
Low:14.98
Close:15.56
52wk High:17.25
52wk Low:4.92
Shares:62.44M
Float Shares:37.01M
Volume Ratio:0.94
T/O Rate:1.49%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.1816
EPS(LYR):-1.2174
ROE:-34.13%
ROA:-22.53%
PB:4.64
PE(LYR):-12.31

Loading ...

PepGen Q2 Net Loss Narrows as Expenses Fall

Reuters
·
Aug 06

RBC Capital Sticks to Their Buy Rating for Design Therapeutics (DSGN)

TIPRANKS
·
Aug 06

Design Therapeutics, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 05

Spyre Therapeutics Q2 Loss Narrower than Expected; Sees Trial Readouts in 2026

Reuters
·
Aug 05

Dianthus Therapeutics Q2 Net Loss Widens as R&D Costs Rise

Reuters
·
Aug 05

Online Deals Firm Giftify's Q2 Net Loss Narrows After Higher Agent Transactions

Reuters
·
Aug 03

Design Therapeutics Q2 Net Loss Narrower than Expected

Reuters
·
Aug 03

Design Therapeutics Q2 EPS $(0.32) Beats $(0.34) Estimate

Benzinga Earnings
·
Aug 03

Design Therapeutics Provides Restore-Fa Clinical Development Update and Reports Second Quarter 2026 Financial Results

THOMSON REUTERS
·
Aug 03

Design Therapeutics Q2 Basic EPS USD -0.32

THOMSON REUTERS
·
Aug 03

Design Therapeutics Q2 Net Income USD -20.165 Million VS. Ibes Estimate USD -21.3 Million

THOMSON REUTERS
·
Aug 03

Press Release: Design Therapeutics Provides Restore-FA Clinical Development Update and Reports Second Quarter 2026 Financial Results

Dow Jones
·
Aug 03

Design Therapeutics Inc Expected to Post a Loss of 34 Cents a Share - Earnings Preview

Reuters
·
Aug 03

Citizens biotech analysts hold an analyst/industry conference call

TIPRANKS
·
Jul 03

Design Therapeutics initiates patient dosing in DT-818 trial

TIPRANKS
·
Jun 30

Design Therapeutics Announces Initiation of Patient Dosing in Phase 1 Multiple Ascending Dose Trial of Dt-818 for Myotonic Dystrophy Type-1

THOMSON REUTERS
·
Jun 30

Design Therapeutics - Expects Phase 1 Dt-818 Data in 2027

THOMSON REUTERS
·
Jun 30

Design Therapeutics Announces Initiation of Patient Dosing in Phase 1 Multiple Ascending Dose Trial of DT-818 for Myotonic Dystrophy Type-1

GlobeNewswire
·
Jun 30

Design Therapeutics Stockholders Approve Director and Auditor at Meeting

TIPRANKS
·
Jun 12

Design Therapeutics shareholders elect Simeon George to board at annual meeting

Reuters
·
Jun 12